Power Law company profile

Rubius Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2013 · IPO 2018 Unicorn

Focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform

Revenue

$13M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

1 investor on Rubius Therapeutics's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 1 investor entered at this stage

Flagship Pioneering

Global footprint

Where Rubius Therapeutics has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States87.5%

🇦🇪 United Arab Emirates12.5%

2 countries shown

Web traffic by country

2.8K monthly visits
across markets

🇦🇺 Australia100%

Top 1 markets shown

Patent intelligence

$1M patent portfolio · 11 active families

Estimated portfolio value

$1M

2236.2× smaller than top peer Illumina ($2.7B)

11 active patent families

Where Rubius Therapeutics innovates Erythroid cellMolecular biologyCell biologyCell systemBiochemistry

Where Rubius Therapeutics concentrates vs peers

Each axis is a top-10 topic across Rubius Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Rubius Therapeutics

An AI-synthesized read of the highest-engagement posts about Rubius Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Rubius Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles